Quantcast
Scientists Develop First Cancer Immunotherapy For Dogs

Scientists Develop First Cancer Immunotherapy For Dogs

University of Veterinary Medicine Vienna Nearly every second dog develops cancer from the age of ten years onward. A few therapies derived from human medicine are available for dogs. A very successful form of therapy by which antibodies...

Latest antibodies Stories

2014-07-10 12:30:51

ST. PETERSBURG, Russia, July 10, 2014 /PRNewswire/ -- On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD [http://biocad.ru/en ]. The Company is developing a unique project called MabNext [http://biocad.ru/en/science ]. Within the scope of MabNext project BIOCAD develops a number of innovative drugs based on monoclonal antibodies for treatment of cancer and autoimmune...

2014-07-09 08:20:35

Milestone Achieved under $9.4 Million NIAID Cooperative Grant PRINCETON, N.J., July 9, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the combination of RiVax(TM) and VeloThrax(TM) induces protective immunity to...

2014-07-03 08:23:49

MUMBAI,India, July 3, 2014 /PRNewswire/ -- - GBR 830 is an antagonistic monoclonal antibody with first in class potential for the treatment of autoimmune diseases targeting OX40, a co-stimulatory receptor on T cells - The antibody has successfully completed the Phase I enabling preclinical development program and a Phase I clinical trial application has been filed with The Netherlands authorities -...

2014-07-01 12:28:27

COLLEGE PARK, Md., July 1, 2014 /PRNewswire-USNewswire/ --The University of Maryland (UMD) Fischell Department of Bioengineering and the Maryland Center for Excellence in Regulatory Science (M-CERSI) have partnered with the Global Biological Standards Institute (GBSI) to launch the Collaboration to Advance Antibody Standards. This collaboration between the Fischell Department of Bioengineering and GBSI will allow for assessment of the current antibody standards landscape and...

2014-07-01 08:30:44

SAN DIEGO, July 1, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received two NIH small business grants which will fund the development of bispecific antibodies for two of its anti-bacterial immunotherapies. Sorrento's highly diverse, fully human G-MAB(®) library and proprietary antibody conjugation technology platforms have...

2014-07-01 08:29:55

Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer THOUSAND OAKS, Calif., July 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational bispecific T cell engager (BiTE(®)) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly...

2014-06-26 23:02:12

Dr. Arash Bereliani, the founder of the IV Therapy Center in Beverly Hills, spoke recently about a new study showing that intravenous vitamin C is useful for patients with Epstein-Barr virus antibodies. Beverly Hills, CA (PRWEB) June 26, 2014 A new study published in the journal Medical Science Monitor has found that patients who have high levels of Epstein-Barr virus (EBV) antibodies can benefit from intravenous vitamin C. The researchers, Nina A. Mikirova and Ronald Hunninghake of...

2014-06-25 08:32:07

SAN DIEGO, June 25, 2014 /PRNewswire/ -- Concortis Biosystems, Inc. (Concortis), a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced a collaboration to generate novel antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology. Under the terms of the agreement, Sorrento will receive...

2014-06-18 23:16:14

Bacterial recombinant protein expression is now available as a service at Maine Biotechnology Services. When MBS develops recombinant antigen for a hybridoma development, the end use application of the antibodies is considered during every phase of antigen production. Portland, Maine (PRWEB) June 18, 2014 Maine Biotechnology Services is announcing the addition of Bacterial Recombinant Protein Expression and Purification services to compliment our complete antibody service offering, adding...

2014-06-18 04:21:10

-- 3SBio's pegsiticase has shown a promising efficacy and safety profile in early clinical trials and Selecta and 3SBio plan to advance clinical studies of pegsiticase-based treatments for refractory and tophaceous gout as well as tumor lysis syndrome SHENYANG, China, June 18, 2014 /PRNewswire/ -- 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.